Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3SBioFRA:83B 86 Forward PE Ratio is 13.91 as of Aug. 05, 2026. GuruFocus rates FRA:83B with a GF Score™ of 86/100 and a GF Value™ of €1.43 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 354 Biotechnology companies, 3SBio ranks better than 64.12% on this metric.
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
3SBio Forward PE Ratio Related Terms
3SBio Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for 3SBio's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
3SBio Forward PE Ratio Chart
3SBio Annual Data
Trend
2019-12
2020-12
2021-12
2022-12
2023-12
2024-12
2025-12
Forward PE Ratio
16.29
10.08
9.45
13.00
7.79
6.12
16.67
3SBio Semi-Annual Data
2019-12
2020-06
2020-12
2021-06
2021-12
2022-06
2022-12
2023-06
2023-12
2024-12
2025-06
2025-12
Forward PE Ratio
16.29
17.67
10.08
19.69
9.45
9.03
13.00
9.56
7.79
6.12
14.64
16.67
FRA:83B vs VRTX, REGN, RVMD: Forward PE Ratio Comparison
For the Biotechnology subindustry, 3SBio's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
3SBio Forward PE Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, 3SBio's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where 3SBio's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
3SBio (FRA:83B) has a Forward PE Ratio of 13.91 as of Aug. 05, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on 3SBio and its competitors. According to the industry distribution chart, 3SBio ranks #127 out of 354 companies in the Biotechnology industry, placing it in the top 35.9%.
Is 3SBio's Forward PE Ratio too high?
3SBio's current Forward PE Ratio is 13.91. The Biotechnology industry median Forward PE Ratio is 22.44. 3SBio's value of 13.91 is 38% below this industry median. Based on the distribution chart, 3SBio ranks #127 out of 354 companies in the Biotechnology industry, which is above the industry midpoint. Overall, 3SBio has a GF Score™ of 86/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does 3SBio's Forward PE Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, 3SBio ranks #127 out of 354 companies for Forward PE Ratio. This puts 3SBio in the upper half of its industry. The industry median Forward PE Ratio is 22.44. 3SBio's value of 13.91 is 38% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Biotechnology company?
The median Forward PE Ratio among Biotechnology companies is 22.44, based on 354 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. 3SBio's current Forward PE Ratio of 13.91 is 38% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on 3SBio and its competitors. For the Biotechnology industry, the median Forward PE Ratio is 22.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 3SBio's current Forward PE Ratio is 13.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 3SBio stock overvalued right now?
Based on GuruFocus' analysis, 3SBio (FRA:83B) is currently considered Modestly Overvalued. The stock's GF Value™ is €1.43, compared to a current price of €1.85 — trading 29.4% above its estimated fair value. The current Forward PE Ratio is 13.91 and 38% below the Biotechnology industry median of 22.44. 3SBio's overall GF Score™ is 86/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For 3SBio (FRA:83B), the current Forward PE Ratio is 13.91 as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 3SBio (FRA:83B) Overvalued in 2026?
Based on GuruFocus' analysis, 3SBio stock appears to be overvalued.
The current stock price of €1.85 is trading 29.4% above its estimated GF Value™ of €1.43.
GuruFocus considers 3SBio to be Modestly Overvalued.
Key valuation signals for FRA:83B:
Forward PE Ratio: 13.91
GF Value™: €1.43 vs. price of €1.85 (29.4% above fair value)
Industry Position: 38% below the Biotechnology median (#127 of 354)
No single metric tells the full story. See the FRA:83B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
3SBio Inc is an investment holding company. It is a primary biotechnology company. The company is principally engaged in the development, production, marketing and sale of biopharmaceutical products in the People's Republic of China. The group has only one operating segment. It has presence in Chinese mainland, USA, Other countries/regions. The majority of revenue comes from USA. The core commercialized products of the group include several bio-pharmaceutical drugs, namely, TPIAO, recombinant human erythropoietin (rhEPO) products EPIAO and SEPO, Yisaipu and Cipterbin, and a small molecule drug, Mandi series of minoxidil drugs.
86GF Score
Get the complete analysis for FRA:83B
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:83B has been successfully added to your 
